The Monkey Head Mushroom and Memory Enhancement in Alzheimer's Disease

Cells. 2022 Jul 24;11(15):2284. doi: 10.3390/cells11152284.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder, and no effective treatments are available to treat this disorder. Therefore, researchers have been investigating Hericium erinaceus, or the monkey head mushroom, an edible medicinal mushroom, as a possible treatment for AD. In this narrative review, we evaluated six preclinical and three clinical studies of the therapeutic effects of Hericium erinaceus on AD. Preclinical trials have successfully demonstrated that extracts and bioactive compounds of Hericium erinaceus have potential beneficial effects in ameliorating cognitive functioning and behavioral deficits in animal models of AD. A limited number of clinical studies have been conducted and several clinical trials are ongoing, which have thus far shown analogous outcomes to the preclinical studies. Nonetheless, future research on Hericium erinaceus needs to focus on elucidating the specific neuroprotective mechanisms and the target sites in AD. Additionally, standardized treatment parameters and universal regulatory systems need to be established to further ensure treatment safety and efficacy. In conclusion, Hericium erinaceus has therapeutic potential and may facilitate memory enhancement in patients with AD.

Keywords: Alzheimer’s disease; Hericium erinaceus; aging; clinical; memory; preclinical.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Animals
  • Cell Extracts / pharmacology
  • Cell Extracts / therapeutic use
  • Disease Models, Animal
  • Hericium* / chemistry
  • Humans
  • Memory* / drug effects
  • Neuroprotection / drug effects

Substances

  • Cell Extracts

Supplementary concepts

  • Hericium erinaceus

Grants and funding

This work was funded by University of Malaya Faculty of Medicine Research Grant GPF003C-2019.